Jean-François Yale

Jean-Francois Yale

Jean-François Yale, MD, CSPQ, FRCPC
Professor, Department of Medicine
Room H685, 687 Pine Avenue West
Montreal, H3A 1A1 Quebec, CANADA

Tel: 514-843-1665

jean-francois.yale [at] mcgill.ca

Biographical Sketch

Dr. Yale is an endocrinologist, currently Professor of Medicine in the Department of Medicine.  Dr. Yale chaired the Clinical and Scientific Section of the CDA from 1992-1994. He chaired the Expert Committee that published the 2001 Canadian Diabetes Association Clinical Practice Guidelines for the Prevention and Management of Hypoglycemia in Diabetes. He was a member of the Steering Committee for the 1998, 2003, 2008 and 2013 CDA Clinical Practice Guidelines.

Keywords

Diabetes, intensive therapy, prevention, complications, hypoglycemia 

Research or Clinical Activities

Dr. Yale’s research interests (210 publications) include the prevention of hypoglycemia in type 1 diabetes, intensive management of type 1 and type 2 diabetes, and he participated in numerous multicentre trials on new therapies for type 1 and type 2 diabetes, including  ACCORD, ORIGIN, DREAM, NAVIGATOR, INSIGHT, AIM@GP, SOLVE, TECOS, SAVOR-TIMI, EXSCEL, REWIND and EAGLE.

Selected Recent Publications

Ligthelm RJ, Kaiser M, Vora J and Yale JF. Insulin Use in Elderly Adults: Risk of Hypoglycemia and Strategies for Care. Journal of the American Geriatrics Society 60 : 1564-1570, 2012

Harper W, Clement M, Goldenbetg R, Hanna A, Main A, Retnakaran R, Sherifali D, Woo V, Yale JF. Pharmacologic Management of Type 2 Diabetes. Can J. Diabetes 37 : S61-68, 2013.

Sullivan MD, Katon W, Lovato L, Miller ME, Murray AM, Horovitz KR, Bryan RN, Gerstein HC, Marcovina S, Akpunonu BE, Johnson J, Yale JF, Williamson J and Launer L.  Depression is associated with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial. JAMA Psychiatry 70 :1041-7, 2013

Harris SB, Yale JF, Berard L, Stewart J, Abbaszadeh B, Webster-Bogaert S and Gerstein HC. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-titration with Apidra to Reach Target) Study – A randomized non-inferiority trial.  Diabetes Care 2013 Oct 29 Epub ahead of print.

Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes and Chronic Kidney Disease). Diabetes, Obesity & Metabolism, 15 :463-73, 2013

PubMed Publications – Jean-François Yale